Summary
Altria Group, Inc.'s (MO) 2020 Form 10-K reveals a company navigating a transitional period, with a stated vision to "responsibly lead the transition of adult smokers to a non-combustible future." While the core business remains dominated by smokeable products, particularly Marlboro cigarettes, which showed stable shipment volumes despite a slight decline, the company is actively investing in and growing its oral tobacco product segment, with 'on!' oral nicotine pouches showing notable volume increases. The company's financial performance in 2020 was significantly impacted by a substantial impairment charge related to its investment in JUUL, amounting to $2.6 billion, following an $8.6 billion charge in 2019. This, along with other special items like those related to investments in ABI and Cronos, contributed to a year-over-year increase in reported net earnings. Altria continues its commitment to shareholder returns through dividends and share repurchases, announcing a new $2.0 billion repurchase program in January 2021. However, the company faces ongoing risks from litigation, evolving regulatory landscapes (particularly from the FDA), excise taxes, and shifts in consumer preferences, all of which are critical factors for investors to consider.
Financial Highlights
52 data points| Revenue | $26.15B |
| Cost of Revenue | $7.82B |
| Gross Profit | $13.02B |
| R&D Expenses | $131.00M |
| Operating Income | $10.87B |
| Interest Expense | $1.22B |
| Net Income | $4.47B |
| EPS (Basic) | $2.40 |
| EPS (Diluted) | $2.40 |
| Shares Outstanding (Basic) | 1.86B |
| Shares Outstanding (Diluted) | 1.86B |
Key Highlights
- 1Altria's primary focus remains on its smokeable products segment, with Marlboro continuing as the leading cigarette brand in the U.S. Shipment volumes for cigarettes remained stable, decreasing by only 0.4% in 2020.
- 2The oral tobacco products segment showed growth, with shipment volume increasing by 1.2%, primarily driven by the 'on!' oral nicotine pouches.
- 3The company recorded a significant $2.6 billion impairment charge related to its investment in JUUL Labs in 2020, following an $8.6 billion impairment in 2019, reflecting the challenges in the e-vapor market and regulatory scrutiny.
- 4Altria's equity investment in Anheuser-Busch InBev (ABI) saw its fair value decline below its carrying value, though management considered this decline to be temporary.
- 5The wine segment, Ste. Michelle, experienced a significant decline in shipment volume (12.0%) and recorded substantial pre-tax charges of $411 million due to inventory write-offs and other costs related to a strategic reset.
- 6Despite a challenging environment, Altria maintained strong operating cash flow and reiterated its commitment to returning capital to shareholders through dividends, with a stated long-term objective of an 80% adjusted diluted EPS payout ratio.
- 7The company is actively managing its debt, completing significant debt transactions in early 2021 to reduce near-term maturities and extend its weighted-average maturity.